Document Type


Publication Date



This article has been peer reviewed. It is the authors' final version prior to publication in Blood

Volume 130, Issue 24, December 2017, Pages 2578-2579.

The published version is available at DOI: 10.1182/blood-2017-10-811091. Copyright © The American Society of Hematology


In a comprehensive study in this issue of Blood, Carden and colleagues describe the importance of the tonicity of IV fluids used in the treatment of patients with sickle cell disease (SCD) during vaso-occlusive crises (VOCs). Hypertonic fluids decreased sickle red blood cell (sRBC) deformability, increased occlusion, and increased sRBC adhesion in microfluidic human microvasculature models. Hypotonic fluids decreased sRBC adhesion but prolonged sRBC transit time. Fluids with intermediate tonicities resulted in optimal changes that reduced the risk of vaso-occlusion. © 2017 by The American Society of Hematology.

PubMed ID


Available for download on Friday, December 14, 2018